Reported preclinical evidence suggests that inflammatory cytokines derived from monocytes or macrophages promoted vascular CXCR4 expression on endothelial cells, while reducing CXCR4 expression by the depletion of macrophages enhanced the anti-tumor impact of sorafenib in liver cancer [102]. This evidence concerns the gene CXCR4 and neoplasm.